Pharmaceutical Technology10 天
Risk adjusted net present value: What is the current valuation of Tempest Therapeutics’s ...
TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC).